GlassScriptPhysician profile
David J Szentes
NPI 1801903372
$1,153.21
in general payments reported to CMS, 2019-2025
25 companies · $129 in 2025
The $129 reported for 2025 was less than what a typical Obstetrics & Gynecology provider received nationally (typical 2025 total: $158).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $424 · 2020: $27.09 · 2021: $14.87 · 2022: $238 · 2023: $147 · 2024: $174 · 2025: $129.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $450.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $449.72 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $184.88 | 2019-2024 | |
| Bayer Healthcare Pharmaceuticals INC. | $180.85 | 2019-2025 | |
| Hologic Sales and Service, LLC | $168.85 | 2019-2024 | Myosure Tissue Removal Device, Acessa Provu System, Novasure |
| Coopersurgical, INC. | $129.79 | 2019-2025 | Paragard T 380a |
| Pfizer INC. | $82.48 | 2019-2024 | |
| Medtronic, INC. | $72.82 | 2022 | |
| Biogen, INC. | $29.26 | 2025 | Zurzuvae |
| Avanos Medical | $29.08 | 2019 | |
| Shield Therapeutics INC | $24.39 | 2025 | |
| Pharmacosmos Therapeutics INC. | $24.13 | 2023 | Monoferric |
| Minerva Surgical, INC | $24.00 | 2019 | |
| Allergan, INC. | $22.04 | 2019 | |
| Astellas Pharma US INC | $20.61 | 2023 | Veozah |
| Pacira Pharmaceuticals Incorporated | $19.21 | 2019 | |
| Medicem INC. | $14.87 | 2021 |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alexion Pharmaceuticals, INC. | $14.51 | 2019 | |
| Amag Pharmaceuticals, INC. | $14.44 | 2019 | |
| Exact Sciences Corporation | $14.26 | 2025 | The Cologuard Plus Collection Kit |
| Covidien LP | $14.22 | 2020 | |
| Merck Sharp & Dohme LLC | $13.44 | 2019 | |
| Lupin INC. | $12.96 | 2019 | |
| Coloplast Corp | $12.87 | 2020 | |
| Kci USA, INC. | $12.50 | 2019 | |
| Duchesnay USA Incorporated | $10.87 | 2019 | |
| Mayne Pharma Commercial LLC | $5.88 | 2025 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw David Szentes listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.